YU49477B - Farmaceutska kompozicija za lokalnu primenu koja sadrži aciklovir i hidrokortizon - Google Patents

Farmaceutska kompozicija za lokalnu primenu koja sadrži aciklovir i hidrokortizon

Info

Publication number
YU49477B
YU49477B YU7296A YU7296A YU49477B YU 49477 B YU49477 B YU 49477B YU 7296 A YU7296 A YU 7296A YU 7296 A YU7296 A YU 7296A YU 49477 B YU49477 B YU 49477B
Authority
YU
Yugoslavia
Prior art keywords
hydrocortisone
pharmaceutical composition
topical application
application containing
containing acyclovir
Prior art date
Application number
YU7296A
Other languages
English (en)
Other versions
YU7296A (sh
Inventor
Johan Georg Harmenberg
Ann Harriet Margareta Kristofferson
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of YU7296A publication Critical patent/YU7296A/sh
Publication of YU49477B publication Critical patent/YU49477B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Farmaceutska kompozicija za dermalnu ili mukoznu primenu, naznačena time, što sadrži kombinaciju protivvirusne supstance, koja je aciklovir i protivzapaljenskog glukokortikoida, koji je hidrokortizon u farmaceutski prihvatljivom nosaču. Prijava sadrži još 4 zavisna patentna zahteva i 2 nezavisna patentna zahteva.
YU7296A 1995-02-06 1996-02-06 Farmaceutska kompozicija za lokalnu primenu koja sadrži aciklovir i hidrokortizon YU49477B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9500114 1995-02-06

Publications (2)

Publication Number Publication Date
YU7296A YU7296A (sh) 1998-08-14
YU49477B true YU49477B (sh) 2006-05-25

Family

ID=20396821

Family Applications (1)

Application Number Title Priority Date Filing Date
YU7296A YU49477B (sh) 1995-02-06 1996-02-06 Farmaceutska kompozicija za lokalnu primenu koja sadrži aciklovir i hidrokortizon

Country Status (30)

Country Link
US (2) US6337324B1 (sh)
EP (2) EP0809498B1 (sh)
JP (2) JP4260220B2 (sh)
KR (1) KR100431042B1 (sh)
CN (1) CN1131034C (sh)
AR (1) AR002030A1 (sh)
AT (2) ATE262907T1 (sh)
AU (1) AU716809B2 (sh)
CA (1) CA2211389C (sh)
DE (3) DE69632034T2 (sh)
DK (1) DK0809498T3 (sh)
DZ (1) DZ1966A1 (sh)
ES (1) ES2214528T3 (sh)
FI (1) FI119415B (sh)
FR (1) FR10C0038I2 (sh)
HK (1) HK1004368A1 (sh)
HR (1) HRP960034B1 (sh)
IL (1) IL116913A0 (sh)
MA (1) MA23800A1 (sh)
MY (1) MY119365A (sh)
NO (1) NO314220B1 (sh)
NZ (1) NZ301407A (sh)
PT (1) PT809498E (sh)
SA (1) SA96160590B1 (sh)
SI (1) SI0809498T1 (sh)
TN (1) TNSN96024A1 (sh)
TW (1) TW438585B (sh)
WO (1) WO1996024355A1 (sh)
YU (1) YU49477B (sh)
ZA (1) ZA96527B (sh)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9601544D0 (en) 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals
IT1287114B1 (it) * 1996-10-31 1998-08-04 Recordati Chem Pharm Composizioni farmaceutiche antierpetiche per applicatori topici, contenenti aciclovir
US7223387B2 (en) 1998-11-18 2007-05-29 Medivir Ab Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
SE9803929D0 (sv) * 1998-11-18 1998-11-18 Medivir Ab Antiviral formulation
US7655252B2 (en) 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US7767216B2 (en) * 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
FR2837102B1 (fr) * 2002-03-18 2004-10-08 Palbian Snc Composition a l'etat de gel aqueux, procede de fabrication et utilisation pour la fabrication d'un medicament, notamment antiherpetique
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
US20050208083A1 (en) * 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
EP1663999A2 (en) * 2003-08-29 2006-06-07 Ranbaxy Laboratories, Ltd. Inhibitors of phosphodiesterase type-iv
EP1694655A2 (en) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US7618950B2 (en) * 2004-07-07 2009-11-17 Arigen Pharmaceuticals, Inc. Method for treatment and prevention of herpes zoster by topical application
CA2602691A1 (en) * 2005-03-30 2006-10-05 Novartis Ag Penciclovir or famciclovir for the treatment of recurrent genital herpes with a one-day application
WO2006110699A1 (en) * 2005-04-11 2006-10-19 Nanobio Corporation Quaternary ammonium halides for treatment of infectious conditions
EP1951200A2 (en) * 2005-08-09 2008-08-06 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US7797337B2 (en) * 2005-09-29 2010-09-14 Scenera Technologies, Llc Methods, systems, and computer program products for automatically associating data with a resource as metadata based on a characteristic of the resource
WO2007045980A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type iv inhibitors
JP2009512676A (ja) 2005-10-19 2009-03-26 ランバクシー ラボラトリーズ リミテッド ムスカリン性受容体アンタゴニストの医薬組成物
FR2900577B1 (fr) * 2006-05-04 2008-09-12 Goemar Lab Sa Nouveaux medicaments pour les traitements contre le virus de l'herpes
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
BRPI0717058A2 (pt) * 2006-09-22 2013-10-15 Ranbaxy Lab Ltd Composto, composição farmacêutica, método para tratar, prevenir, inibir ou suprimir uma condição inflamatória ou doença ou doenças do sistema nervoso central e método para a preparação de um composto
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
CA2680625C (en) * 2007-03-14 2016-02-23 Ranbaxy Laboratories Limited Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
EP2155209A4 (en) * 2007-04-26 2012-06-13 Univ Pennsylvania DNA polymerase inhibitor composition and method
EP2152304B1 (en) 2007-05-02 2018-08-22 The Regents of the University of Michigan Nanoemulsion therapeutic compositions and methods of using the same
JP4972062B2 (ja) * 2008-03-17 2012-07-11 メディヴィル・アクチエボラーグ 抗ウイルス製剤
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
US20090291895A1 (en) * 2008-05-23 2009-11-26 Wong Scott W Methods and Compositions for the Treatment of Inflammatory Diseases
US20110065655A1 (en) * 2009-09-17 2011-03-17 Karry Whitten Therapeutic composition to treat lesions caused by herpes simplex virus
CN102049050B (zh) * 2009-11-02 2014-06-18 重庆华邦制药有限公司 抗疱疹病毒感染的药物组合物
EP2489354A1 (en) * 2011-02-18 2012-08-22 Vironova AB Pharmaceutical formulation of B220 for topical treatment of herpes
ITMI20111747A1 (it) * 2011-09-28 2013-03-29 Fidia Farmaceutici Composizioni farmaceutiche topiche comprendenti aciclovir
FR2983731B1 (fr) * 2011-12-07 2014-04-25 Univ Paris Descartes Emulsions topiques a base de melanges eutectiques d'anesthesiques locaux et d'acide gras
US10682370B2 (en) * 2013-03-13 2020-06-16 Nal Pharmaceutical Group Limited Topical antiviral composition containing a local anesthetic and method of making the same
CN104324039A (zh) * 2014-10-20 2015-02-04 付茜 一种治疗人身体表面脂肪瘤的药剂及使用方法
CN108853140A (zh) * 2018-07-18 2018-11-23 豆立忠 一种多药物模块软膏及其制备方法
WO2020036545A1 (en) * 2018-08-17 2020-02-20 İlko İlaç Sanayi̇ Ve Ti̇caret A.Ş. Phase stable topical composition comprising acyclovir and hydrocortisone
CA3142831A1 (en) 2019-06-14 2020-12-17 Propella Therapeutics, Inc. Topical acyclovir formulations and uses thereof
CN112569243A (zh) * 2019-09-30 2021-03-30 神农医药科技有限公司 制备治疗阿尔茨海默病的药物
EP4149443A4 (en) * 2020-05-11 2024-05-29 Revir, Inc. COMPOSITIONS AND METHODS FOR TREATING VIRUS INFECTIONS
CN112704154A (zh) * 2020-12-24 2021-04-27 中国人民解放军66399部队 一种用于治疗宠物猫疱疹病毒的营养膏
US11951082B2 (en) 2022-08-22 2024-04-09 Ford Therapeutics, Llc Composition of chlorhexidine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3317384A (en) 1964-06-08 1967-05-02 Upjohn Co Treatment of topical viral infections with glucocorticoids and nucleosides
US4512978A (en) * 1980-01-24 1985-04-23 Inwood Louis R Dermatological composition useful in the treatment of psoriasis
US4902678A (en) * 1982-02-12 1990-02-20 Syntex (U.S.A.) Inc. Anti-viral compositions
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
EP0594223B1 (en) * 1985-09-17 2000-03-01 The Wellcome Foundation Limited Combination of therapeutic nucleosides and further therapeutic agents.
US5023090A (en) 1989-08-16 1991-06-11 Levin Robert H Topical compositions containing LYCD and other topically active medicinal ingredients for the treatment of ACNE
US4942031A (en) 1988-02-23 1990-07-17 Levin Robert H Compositions containing LYCD and other topically active medicinal ingredients
WO1990006775A1 (en) * 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
AU636255B2 (en) * 1990-11-05 1993-04-22 Arthropharm Pty Ltd Use of a topical formulation for the treatment of viral infections and neoplastic disorders
US5856364A (en) * 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
JPH06507404A (ja) * 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
IL104283A (en) * 1992-12-30 1996-12-05 Agis Ind 1983 Ltd Non-emulsion antiviral topical pharmaceutical composition comprising acyclovir an aqueous gel agent and an alkali oleate
GB9315755D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized formulation
DZ1965A1 (fr) * 1995-02-06 2002-07-17 Astra Ab Composition pharmaceutique nouvelle.
GB9601544D0 (en) 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals

Also Published As

Publication number Publication date
JP2007284452A (ja) 2007-11-01
NO973612D0 (no) 1997-08-05
HK1004368A1 (en) 1998-11-27
EP1419803A2 (en) 2004-05-19
CA2211389C (en) 2007-11-20
CA2211389A1 (en) 1996-08-15
SI0809498T1 (en) 2004-12-31
FI973243A0 (fi) 1997-08-06
MA23800A1 (fr) 1996-10-01
PT809498E (pt) 2004-06-30
AU4682196A (en) 1996-08-27
JPH11506417A (ja) 1999-06-08
USRE39264E1 (en) 2006-09-05
TW438585B (en) 2001-06-07
JP4260220B2 (ja) 2009-04-30
CN1131034C (zh) 2003-12-17
KR19980701959A (ko) 1998-06-25
HRP960034A2 (en) 1997-10-31
FI973243A (fi) 1997-08-06
ATE421358T1 (de) 2009-02-15
NO973612L (no) 1997-09-26
HRP960034B1 (en) 2002-02-28
ATE262907T1 (de) 2004-04-15
IL116913A0 (en) 1996-05-14
EP0809498B1 (en) 2004-03-31
TNSN96024A1 (fr) 2005-03-15
DE69637828D1 (de) 2009-03-12
YU7296A (sh) 1998-08-14
EP1419803B1 (en) 2009-01-21
DZ1966A1 (fr) 2002-10-15
DE69632034T2 (de) 2004-10-14
FI119415B (fi) 2008-11-14
KR100431042B1 (ko) 2004-06-16
NO314220B1 (no) 2003-02-17
AU716809B2 (en) 2000-03-09
US6337324B1 (en) 2002-01-08
EP1419803A3 (en) 2004-06-09
ZA96527B (en) 1996-08-06
SA96160590B1 (ar) 2005-10-05
FR10C0038I2 (sh) 2011-04-29
DK0809498T3 (da) 2004-05-10
AR002030A1 (es) 1998-01-07
ES2214528T3 (es) 2004-09-16
NZ301407A (en) 1999-01-28
WO1996024355A1 (en) 1996-08-15
EP0809498A1 (en) 1997-12-03
CN1179718A (zh) 1998-04-22
FR10C0038I1 (sh) 2010-10-15
DE69632034D1 (de) 2004-05-06
MY119365A (en) 2005-05-31
DE122010000032I1 (de) 2010-10-21

Similar Documents

Publication Publication Date Title
YU49477B (sh) Farmaceutska kompozicija za lokalnu primenu koja sadrži aciklovir i hidrokortizon
ATE165971T1 (de) Ein definiertes lipidsystem enthaltende pharmazeutische zusammensetzung
AU7474187A (en) Novel anti-inflammatory agents, pharmaceutical compositions and methods for reducing inflammation
BG103664A (en) Pharmaceutical forms containing ammoxycillin and clavulanate
NZ512792A (en) Stable liquid interferon beta formulations
CA2184433A1 (en) Retinoid Formulations in Porous Microspheres for Reduced Irritation and Enhanced Stability
AU2792997A (en) Medicinal compositions for topical administration containing vitamin d and vitamin k
IT8821324A0 (it) Composizioni farmaceutiche ad attivita' analgesica ed antiinfiammatoria per uso orale, dotate di ottima palatabilita' ed esenti da effetti irritanti sulle mucose.
BR9610983A (pt) Formas estáveis de administração farmacêuticas contendo paratormônio
AU6829287A (en) Stabilised formulations of alpha-interferon
MX9603596A (es) Perfluoropolieteres o composiciones de los mismos para prevencion y tratamiento de infecciones virales topicas.
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
ES2181763T3 (es) Formulaciones a base de fenbendazol.
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
LT96093A (en) The active ingredient of pharmaceutical composition for treating aphtae and stomatitis
DE69631132D1 (de) Orale arzneimittel zubereitung von piperdinoalkanole in gelöster form
ATE196914T1 (de) Lh-rh analoge mit starrer konformation, deren verwendungen und pharmazeutische zusammensetzungen
AU6944696A (en) Novel phenylacetic acid derivatives and medicinal composition containing the same
AU9221898A (en) Pharmaceutical coating composition and method of use
KR970001311A (ko) 에틸 아미도 플루오렌 유도체 및 이를 함유한 약제조성물
DK0927031T3 (da) Farmaceutisk sammensætning indeholdende nimesulid til oral admnistration
AU3992897A (en) Use of sulbutiamine to obtain pharmaceutical compositions useful in the treatment of certain psychomotor and psycho-intellectual disorders
ATE102934T1 (de) Fluorierte flavon-essigsaeure.
AU4655596A (en) Liquid stable vitamin c compositions and delivery systems, and methods of making and uses thereof
AU4633296A (en) Novel benzamidine derivatives and medicinal composition thereof